Recently, interest has developed regarding the possibility of targeting
intracellular inhibitory proteins to improve T cell activity against cancer, including diacylglycerol kinase ζ (DGKζ)(9, 10) and Casitas b - lineage proto - oncogene b (Cbl - b)(11), which attenuate
signal transduction
events downstream of the TCR and CD28.